Hematology CME Courses
Hematology CME Courses
Acute lymphoblastic leukemia (ALL) is one of a group of malignancies caused by cytogenetic DNA mutations of developing hematopoietic stem cell precursors and mostly common to children with peak incidence at 2-5 years of age. Although approximately 80% of ALL cases present in children, they also occur in adults. The symptoms of ALL are non-specific and similar to those of acute myelogenous leukemia (AML), which patients usually have 1-3 months of complaints.
By the end of the session the participant will be able to:
- Summarize the most impactful findings presented at ASH 2015 relating to ALL and apply them to patient cases, taking into account any relevant barriers to care.
- Additional objectives to be dictated by clinical content
Multiple myeloma (MM) is a hematologic malignancy of the lymphocytes. All cases are marked by monoclonal gammopathy, and while the true cause is unknown, associated factors are thought to include: radiation, genetics, viral infections, and the human immunodeficiency virus. Helping the clinician discern the role of each of the first-line and more novel therapies, including monoclonal antibodies and proteasome, deacetylase, and 3 serine/threonine protein kinase inhibitor therapies – among others – based on the most up-to-date research merits continuing education programming in MM.
By the end of the session the participant will be able to:
- Recall updates in the staging, prognosis, and diagnosis of MM.
- Distinguish between the most appropriate treatment approaches to MM and apply them to practice, taking into account the following: treatment modalities and the recent clinical trial evidence supporting them.
- Distinguish between the most appropriate treatment approaches to MM and apply them to practice, taking into account the following: evidence-based treatment guidelines, algorithms, and expert opinion.
- Summarize the risk-benefit profiles of current and emerging therapies for the treatment of MM.